размер рынка лечения рака, доля и статистика отрасли к 2029 году

Q: What is the growth rate of the cancer treatment market?

The growth rate of the cancer treatment market is 12.1%. Read More

Global Cancer Treatment Market

Размер рынка в млрд долларов США

CAGR : 12.10 %

Прогнозируемый период	2022 –2029
Размер рынка (базовый год)	USD 215,900.00 Million
Размер рынка (прогнозируемый год)	USD 524,921.84 Million
CAGR	12.10 %
Основные игроки рынка	Bristol Myers Squibb Company F. Hoffman La Roche Ltd Clegen AbbVie Pfizer

>Глобальный рынок лечения рака по типу рака (рак молочной железы, колоректальный рак с метастазами в печень, карцинома легких, рак предстательной железы, рак яичников, рак головы и шеи, рак поджелудочной железы, глиобластома, почечно-клеточная карцинома, анапластическая карцинома щитовидной железы, саркома и другие), лечение (лекарства, таргетная терапия, радиотерапия, хирургия и другие), способ введения (инъекционный, пероральный и другие), конечный пользователь (больницы, специализированные клиники), страна (США, Канада, Германия, Франция, Великобритания, Италия, Испания, Россия, Турция, Бельгия, Венгрия, Нидерланды, Швейцария, Литва, Австрия, Норвегия, Ирландия, Польша и остальная Европа, Австралия) — тенденции отрасли и прогноз до 2029 года

Анализ рынка и аналитика : глобальный рынок лечения рака

Ожидается, что мировой рынок лечения рака будет расти в прогнозируемый период с 2022 по 2029 год. По данным Data Bridge Market Research, рынок растет со среднегодовым темпом роста 12,1% в прогнозируемый период с 2022 по 2029 год и, как ожидается, достигнет 524 921,84 млн долларов США к 2029 году по сравнению с 215 900,00 млн долларов США в 2021 году. Высокая распространенность рака и растущая деятельность в области НИОКР для его эффективного применения, вероятно, станут основными факторами, которые будут стимулировать спрос на рынке в прогнозируемый период.

Рак — это заболевание, при котором некоторые клетки организма растут неконтролируемо и в конечном итоге распространяются на другие части тела. Раковая опухоль распространяется на близлежащие ткани и может перемещаться в отдаленные места внутри тела, образуя новую опухоль. Этот процесс называется метастазами. Раковую опухоль также называют злокачественной опухолью. Доброкачественная опухоль не проникает в близлежащие ткани, и после удаления доброкачественные опухоли обычно не вырастают снова, тогда как раковые опухоли иногда вырастают снова.

Существует более ста типов рака. Некоторые категории рака, которые начинаются в определенных типах клеток, включают карциному, саркому, лейкемию, лимфому и множественную миелому, среди прочих. В зависимости от типа рака доступны многие типы лечения рака. Лечение рака включает тестирование биомаркеров для лечения рака, химиотерапию, гормональную терапию, гипертермию, иммунотерапию, фотодинамическую терапию, лучевую терапию, хирургию, трансплантацию стволовых клеток и таргетную терапию.

По данным GLOBOCAN, в 2020 году во всем мире было выявлено 19 292 789 новых случаев рака. Больше всего случаев было выявлено у рака груди. Поэтому ожидается, что высокая распространенность рака, инициативы правительства по повышению осведомленности и раннему выявлению рака, а также продолжающиеся клинические испытания будут способствовать росту рынка.

Ожидается, что высокая распространенность рака, рост гериатрического рака и доступность современных таргетных методов лечения рака станут движущей силой роста рынка. Однако высокая стоимость и побочные эффекты лечения могут сдерживать рост рынка. Ожидается, что рост одобрения продукции станет возможностью для роста рынка. Однако отсутствие раннего выявления заболеваний может поставить под угрозу рост рынка.

Отчет о мировом рынке лечения рака содержит сведения о доле рынка, новых разработках и влиянии отечественных и локальных игроков рынка, анализирует возможности с точки зрения новых источников дохода, изменений в рыночных правилах, одобрений продуктов, стратегических решений, запусков продуктов, географических расширений и технологических инноваций на рынке. Чтобы понять анализ и рыночный сценарий, свяжитесь с нами для получения аналитического резюме. Наша команда поможет вам создать решение по влиянию на доход для достижения желаемой цели.

Масштаб и размер мирового рынка лечения рака

Глобальный рынок лечения рака подразделяется на четыре заметных сегмента на основе типа рака, лечения, пути введения и конечного пользователя. Рост среди сегментов помогает вам анализировать нишевые карманы роста и стратегии для выхода на рынок и определять ваши основные области применения и разницу в ваших целевых рынках.

На основе типа рака глобальный рынок лечения рака сегментирован на рак груди, колоректальный рак с метастазами в печень, карциному легких, рак простаты, рак яичников, рак головы и шеи, рак поджелудочной железы, глиобластому, почечно-клеточную карциному, анапластическую карциному щитовидной железы и саркому. Ожидается, что в 2022 году сегмент рака груди будет доминировать на рынке из-за растущей правительственной инициативы и правительственных кампаний по повышению осведомленности и ранней диагностики и лечения рака груди.
На основе лечения глобальный рынок лечения рака сегментируется на лекарственные препараты, таргетную терапию, радиотерапию, хирургию и др. Ожидается, что в 2022 году сегмент лекарственных препаратов будет доминировать на рынке из-за увеличения числа запусков, растущего одобрения FDA различных типов лекарств и сильного присутствия продуктов, находящихся в разработке.
На основе способа введения мировой рынок лечения рака сегментируется на инъекционные, пероральные и др. Ожидается, что в 2022 году сегмент инъекционных препаратов будет доминировать на рынке, поскольку это наиболее актуальная форма введения лекарств.
На основе конечного пользователя глобальный рынок лечения рака сегментирован на больницы и специализированные клиники. Ожидается, что в 2022 году сегмент больниц будет доминировать на рынке, поскольку богатые больницы в развитых и развивающихся странах предъявляют высокие требования к передовому лечению рака из-за растущей обеспокоенности пациентов по поводу здоровья.

Анализ мирового рынка лечения рака на уровне страны

Проведен анализ мирового рынка лечения рака, а также предоставлена информация о размерах рынка по географии, типу рака, лечению, способу введения и конечному пользователю.

В отчете о мировом рынке лечения рака рассматриваются следующие страны: США, Канада, Германия, Франция, Великобритания, Италия, Испания, Россия, Турция, Бельгия, Венгрия, Нидерланды, Швейцария, Литва, Австрия, Норвегия, Ирландия, Польша, а также страны остальной Европы и Австралия.

Ожидается, что США будут доминировать на мировом рынке лечения рака в регионе Северной Америки из-за крупнейшего потребительского рынка с высоким ВВП, роста числа онкологических больных и множества игроков, присутствующих на рынке. Прогнозируется, что Германия будет доминировать на рынке лечения рака в регионе Европы из-за наличия неиспользованных возможностей в Германии, возросшего спроса на лечение рака и растущего гериатрического населения в Германии. Ожидается, что сегмент рака груди будет доминировать на рынке из-за растущей правительственной инициативы и правительственных кампаний по повышению осведомленности и ранней диагностике и лечению рака груди.

Раздел отчета по странам также содержит отдельные факторы, влияющие на рынок, и изменения в регулировании рынка, которые влияют на текущие и будущие тенденции рынка. Такие данные, как новые продажи, замещающие продажи, демографические данные страны, нормативные акты и импортно-экспортные тарифы, являются одними из основных указателей, используемых для прогнозирования рыночного сценария для отдельных стран. Кроме того, при предоставлении прогнозного анализа данных по стране учитываются наличие и доступность глобальных брендов и их проблемы из-за большой или малой конкуренции со стороны местных и отечественных брендов, влияние каналов продаж.

Технологические разработки и государственно-частное финансирование создают возможности на мировом рынке лечения рака

Глобальный рынок лечения рака также предоставляет вам подробный анализ рынка для роста каждой страны в определенной отрасли с продажами устройств для дебридмента ран, влиянием прогресса на рынке, изменениями в сценариях регулирования с их поддержкой рынка лечения рака. Данные доступны за исторический период с 2011 по 2020 год.

Анализ конкурентной среды и доли мирового рынка лечения рака

Конкурентная среда мирового рынка лечения рака содержит сведения о конкуренте. Включены сведения о компании, финансах компании, полученном доходе, рыночном потенциале, инвестициях в исследования и разработки, новых рыночных инициативах, производственных площадках и объектах, сильных и слабых сторонах компании, запуске продукта, испытаниях продукта, одобрении продукта, патентах, широте продукта и дыхании, доминировании приложений, жизненно важной кривой технологии. Приведенные выше данные относятся только к фокусу компании на мировом рынке лечения рака.

К числу крупнейших компаний, работающих на мировом рынке лечения рака, относятся Bristol-Myers Squibb Company, F. Hoffman La-Roche Ltd, Clegen, AbbVie, Inc., Pfizer, Inc. и Novartis AG, а также другие.

Стратегические инициативы участников рынка и новые технологические достижения в лечении рака сокращают разрыв между различными методами лечения.

Например,

В декабре 2020 года компания F. Hoffman-La Roche Ltd. объявила о получении одобрения Управления по контролю за продуктами и лекарствами США на свой препарат Gavreto для лечения детей старше 12 лет и взрослых пациентов с прогрессирующим или метастатическим перестроенным в ходе трансфекции-мутантного медуллярным раком щитовидной железы, требующим системной терапии. Это помогло компании расширить свой портфель.

Сотрудничество, совместные предприятия и другие стратегии участников рынка расширяют возможности компании на рынке лечения рака, что также позволяет организации улучшить свое предложение на мировом рынке лечения рака.

SKU-67335

Get online access to the report on the World's First Market Intelligence Cloud

Click on image to enlarge

Интерактивная панель анализа данных
Панель анализа компании для возможностей с высоким потенциалом роста
Доступ аналитика-исследователя для настройки и запросов
Анализ конкурентов с помощью интерактивной панели
Последние новости, обновления и анализ тенденций
Используйте возможности сравнительного анализа для комплексного отслеживания конкурентов

Запросить демонстрацию

Содержание

1 INTRODUCTION

1.1 OBJECTIVES OF THE STUDY

1.2 MARKET DEFINITION

1.3 OVERVIEW OF GLOBAL, EUROPE, AUSTRALIA, U.S. CANCER TREATMENT MARKET

1.4 LIMITATIONS

1.5 MARKETS COVERED

2 MARKET SEGMENTATION

2.1 MARKETS COVERED

2.2 GEOGRAPHICAL SCOPE

2.3 YEARS CONSIDERED FOR THE STUDY

2.4 CURRENCY AND PRICING

2.5 DBMR TRIPOD DATA VALIDATION MODEL

2.6 MULTIVARIATE MODELLING

2.7 CANCER TYPE LIFELINE CURVE

2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS

2.9 VENDOR SHARE ANALYSIS

2.1 SECONDARY SOURCES

2.11 ASSUMPTIONS

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

4.1 PESTEL ANALYSIS

4.2 PORTERS FIVE FORCES

5 EPIDEMOLOGY

6 GLOBAL, EUROPE, AUSTRALIA & U.S. CANCER TREATMENT MARKET: REGULATORY SCENARIO

6.1 TIMELINE TO APPROVE A DRUG

7 MARKET OVERVIEW

7.1 DRIVERS

7.1.1 GROWING CANCER BURDEN WORLDWIDE

7.1.2 GROWING GERIATRIC POPULATION

7.1.3 AVAILABILITY OF DIFFERENT TYPES OF TARGETED THERAPIES

7.1.4 RISING NUMBER OF FDA APPROVAL

7.1.5 GROWING R&D ACTIVITIES

7.2 RESTRAINTS

7.2.1 ADVERSE EFFECTS AND RISKS ASSOCIATED WITH CANCER TREATMENT DRUGS

7.2.2 HIGH COST OF CANCER TREATMENT

7.2.3 LACK OF EARLY DETECTION

7.3 OPPORTUNITIES

7.3.1 STRATEGIC DEVELOPMENT AMONG MAJOR PLAYERS

7.3.2 INCREASING INITIATIVES BY GOVERNMENT AND OTHER HEALTHCARE ORGANIZATIONS

7.3.3 RISING EXPENDITURE ON CANCER TREATMENT

7.4 CHALLENGES

7.4.1 PATENT EXPIRY OF DRUGS

8 GLOBAL, EUROPE, AUSTRALIA & U.S. CANCER TREATMENT MARKET, BY CANCER TYPE

8.1 OVERVIEW

8.2 BREAST CANCER

8.3 COLORECTAL CANCER WITH LIVER METASTASES

8.4 LUNG CARCINOMA

8.5 PROSTATE CANCER

8.6 OVARIAN CANCER

8.7 HEAD-AND-NECK CANCER

8.8 PANCREATIC CANCER

8.9 GLIOBLASTOMA

8.1 RENAL CELL CARCINOMA

8.11 ANAPLASTIC THYROID CARCINOMA

8.12 SARCOMA

9 GLOBAL, EUROPE, AUSTRALIA & U.S. CANCER TREATMENT MARKET, BY TREATMENT

9.1 OVERVIEW

9.2 MEDICATION

9.2.1 BY DRUG TYPE

9.2.1.1 LUNG CARCINOMA

9.2.1.1.1 NIVOLUMAB (OPDIVO)

9.2.1.1.2 BEVACIZUMAB (AVASTIN)

9.2.1.1.3 CRIZOTINIB (XALKORI)

9.2.1.1.4 ERLOTINIB (TARCEVA)

9.2.1.1.5 GEFITINIB (IRESSA)

9.2.1.1.6 AFATINIB DIMALEATE (GILOTRIF)

9.2.1.1.7 CERITINIB (LDK378/ZYKADIA)

9.2.1.1.8 RAMUCIRUMAB (CYRAMZA)

9.2.1.1.9 OTHERS

9.2.1.2 COLORECTAL CANCER WITH LIVER METASTASES

9.2.1.2.1 NIVOLUMAB (OPDIVO)

9.2.1.2.2 CETUXIMAB (ERBITUX)

9.2.1.2.3 PANITUMUMAB (VECTIBIX)

9.2.1.2.4 BEVACIZUMAB (AVASTIN)

9.2.1.2.5 ZIV-AFLIBERCEPT (ZALTRAP)

9.2.1.2.6 REGORAFENIB (STIVARGA)

9.2.1.2.7 RAMUCIRUMAB (CYRAMZA)

9.2.1.2.8 IPILIMUMAB (YERVOY)

9.2.1.2.9 ENCORAFENIB (BRAFTOVI)

9.2.1.2.10 PEMBROLIZUMAB (KEYTRUDA)

9.2.1.2.11 OTHERS

9.2.1.3 OVARIAN CANCER

9.2.1.3.1 BEVACIZUMAB (AVASTIN)

9.2.1.3.2 OLAPARIB (LYNPARZA)

9.2.1.3.3 RUCAPARIB CAMSYLATE (RUBRACA)

9.2.1.3.4 NIRAPARIB TOSYLATE MONOHYDRATE (ZEJULA)

9.2.1.3.5 OTHERS

9.2.1.4 HEAD-AND-NECK CANCER

9.2.1.4.1 CETUXIMAB (ERBITUX)

9.2.1.4.2 PEMBROLIZUMAB (KEYTRUDA)

9.2.1.4.3 NIVOLUMAB (OPDIVO)

9.2.1.4.4 OTHERS

9.2.1.5 RENAL CELL CARCINOMA

9.2.1.5.1 NIVOLUMAB (OPDIVO)

9.2.1.5.2 BEVACIZUMAB (AVASTIN)

9.2.1.5.3 SORAFENIB (NEXAVAR)

9.2.1.5.4 SUNITINIB (SUTENT)

9.2.1.5.5 PAZOPANIB (VOTRIENT)

9.2.1.5.6 TEMSIROLIMUS (TORISEL)

9.2.1.5.7 EVEROLIMUS (AFINITOR)

9.2.1.5.8 AXITINIB (INLYTA)

9.2.1.5.9 CABOZANTINIB (CABOMETYX)

9.2.1.5.10 OTHERS

9.2.1.6 ANAPLASTIC THYROID CARCINOMA

9.2.1.6.1 CABOZANTINIB (COMETRIQ)

9.2.1.6.2 VANDETANIB (CAPRELSA)

9.2.1.6.3 SORAFENIB (NEXAVAR)

9.2.1.6.4 LENVATINIB MESYLATE (LENVIMA)

9.2.1.6.5 TRAMETINIB (MEKINIST)

9.2.1.6.6 DABRAFENIB (TAFINLAR)

9.2.1.6.7 SELPERCATINIB (RETEVMO)

9.2.1.6.8 PRALSETINIB (GAVRETO)

9.2.1.6.9 OTHERS

9.2.1.7 BREAST CANCER

9.2.1.7.1 EVEROLIMUS (AFINITOR)

9.2.1.7.2 TAMOXIFEN (NOLVADEX)

9.2.1.7.3 TRASTUZUMAB (HERCEPTIN)

9.2.1.7.4 FULVESTRANT (FASLODEX)

9.2.1.7.5 ANASTROZOLE (ARIMIDEX)

9.2.1.7.6 EXEMESTANE (AROMASIN)

9.2.1.7.7 LETROZOLE (FEMARA)

9.2.1.7.8 PERTUZUMAB (PERJETA)

9.2.1.7.9 PALBOCICLIB (IBRANCE)

9.2.1.7.10 RIBOCICLIB (KISQALI)

9.2.1.7.11 TOSYLATE (TALZENNA)

9.2.1.7.12 PEMBROLIZUMAB (KEYTRUDA)

9.2.1.7.13 MARGETUXIMAB-CMKB (MARGENZA)

9.2.1.7.14 OTHERS

9.2.1.8 PROSTATE CANCER

9.2.1.8.1 CABAZITAXEL (JEVTANA)

9.2.1.8.2 ENZALUTAMIDE (XTANDI)

9.2.1.8.3 ABIRATERONE ACETATE (ZYTIGA)

9.2.1.8.4 RADIUM 223 DICHLORIDE (XOFIGO)

9.2.1.8.5 APALUTAMIDE (ERLEADA)

9.2.1.8.6 DAROLUTAMIDE (NUBEQA)

9.2.1.8.7 RUCAPARIB CAMSYLATE (RUBRACA)

9.2.1.8.8 OLAPARIB (LYNPARZA)

9.2.1.8.9 OTHERS

9.2.1.9 PANCREATIC CANCER

9.2.1.9.1 ERLOTINIB (TARCEVA)

9.2.1.9.2 EVEROLIMUS (AFINITOR)

9.2.1.9.3 SUNITINIB (SUTENT)

9.2.1.9.4 OLAPARIB (LYNPARZA)

9.2.1.9.5 BELZUTIFAN (WELIREG)

9.2.1.9.6 OTHERS

9.2.1.10 GLIOBLASTOMA

9.2.1.10.1 BEVACIZUMAB (AVASTIN)

9.2.1.10.2 EVEROLIMUS (AFINITOR)

9.2.1.10.3 BELZUTIFAN (WELIREG)

9.2.1.10.4 OTHERS

9.2.1.11 SARCOMA

9.2.1.11.1 COSMEGEN (DACTINOMYCIN)

9.2.1.11.2 DACTINOMYCIN

9.2.1.11.3 DOXORUBICIN HYDROCHLORIDE

9.2.1.11.4 ERIBULIN MESYLATE

9.2.1.11.5 GLEEVEC (IMATINIB MESYLATE)

9.2.1.11.6 HALAVEN (ERIBULIN MESYLATE)

9.2.1.11.7 IMATINIB MESYLATE

9.2.1.11.8 PAZOPANIB HYDROCHLORIDE

9.2.1.11.9 TAZEMETOSTAT HYDROBROMIDE

9.2.1.11.10 TAZVERIK (TAZEMETOSTAT HYDROBROMIDE)

9.2.1.11.11 TRABECTEDIN

9.2.1.11.12 VOTRIENT (PAZOPANIB HYDROCHLORIDE)

9.2.1.11.13 YONDELIS (TRABECTEDIN)

9.2.1.11.14 OTHERS

9.2.2 BY VACCINES

9.2.2.1 CERVARIX

9.2.2.2 GARDASIL

9.2.2.3 GARDASIL-9

9.2.2.4 HEPATITIS B (HBV) VACCINE (HEPLISAV-B)

9.2.2.5 SIPULEUCEL-T (PROVENGE)

9.2.2.6 OTHERS

9.3 RADIOTHERAPY

9.3.1 EXTERNAL BEAM RADIATION THERAPY

9.3.1.1 THREE -DIMENSIONAL CONFROMAL RADIATION THERAPY (3-D CRT)

9.3.1.2 PROTON THERAPY

9.3.1.3 INTENSITY-MODULATED RADIATION THERAPY (IMRT)

9.3.1.4 IMAGE-GUIDED RADIATION THERAPY (IGRT)

9.3.1.5 TOMOTHERAPY

9.3.1.6 STEREOTACTIC RADIOSURGERY

9.3.1.7 STEREOTACTIC BODY RADIATION THERAPY (SRT)

9.3.1.8 INTRAOPERATIVE RADIATION THERAPY

9.3.1.9 OTHERS

9.3.2 INTERNAL RADIATION THERAPY (BRACHYTHERAPY)

9.3.2.1 LOW-DOSE-RATE (LDR) BRACHYTHERAPY

9.3.2.2 HIGH-DOSE-RATE (HDR) BRACHYTHERAPY

9.3.3 SYSTEMIC RADIATION THERAPY

9.3.3.1 PEPTIDE RECEPTOR RADIONUCLIDE THERAPY (PRRT)

9.3.3.2 OTHERS

9.4 SURGERY

9.4.1 PAROTIDECTOMY

9.4.2 ENDOSCOPIC SURGERY

9.4.3 NECK DISSECTION

9.4.4 RECONSTRUCTIVE SURGERY

9.4.5 OTHERS

9.5 TARGETED THERAPIES

9.5.1 SMALL MOLECULES

9.5.1.1 TYROSINE & SERINE/THREONINE KINASES

9.5.1.1.1 IMATINIB (GLEEVEC)

9.5.1.1.2 GEFITINIB (IRESSA)

9.5.1.1.3 ERLOTINIB (TARCEVA)

9.5.1.1.4 SUNITINIB (SUTENT)

9.5.1.1.5 PERIFOSINE

9.5.1.1.6 OTHERS

9.5.1.2 PROTEOSOMES

9.5.1.2.1 BORTEZOMIB (VELCADE)

9.5.1.2.2 CARFILZOMIB (KYPROLIS)

9.5.1.2.3 MARIZOMIB

9.5.1.3 MMPS AND HSPS

9.5.1.3.1 BATIMASTAT

9.5.1.3.2 NEOVASTAT

9.5.1.3.3 PRINOMASTAT

9.5.1.3.4 REBIMASTAT

9.5.1.3.5 GANETESPIB

9.5.1.3.6 OTHERS

9.5.1.4 APOPTOSIS

9.5.1.4.1 OBATOCLAX

9.5.1.4.2 NAVITOCLAX

9.5.1.4.3 OTHERS

9.5.2 IMMUNOTHERAPY

9.5.2.1 IMMUNE CHECKPOINT INHIBITORS

9.5.2.2 T-CELL TRANSFER THERAPY

9.5.2.2.1 TIL THERAPY

9.5.2.2.2 CAR T-CELL THERAPY

9.5.2.2.3 BY PRODUCT

9.5.2.2.3.1 TISAGENLECLEUCEL (KYMRIAH)

9.5.2.2.3.2 AXICABTAGENE CILOLEUCEL (YESCARTA)

9.5.2.2.3.3 BREXUCABTAGENE AUTOLEUCEL (TECARTUS)

9.5.2.2.3.4 OTHERS

9.5.2.2.4 BY TECHNOLOGY

9.5.2.2.4.1 AUTOLOGOUS

9.5.2.2.4.2 ALLOGENEIC

9.5.2.3 MONOCLONAL ANTIBODIES

9.5.2.3.1 RITUXIMAB

9.5.2.3.2 BLINATUMOMAB (BLINCYTO)

9.5.2.3.3 OTHERS

9.5.2.4 IMMUNE SYSTEM MODULATORS

9.5.2.4.1 CYTOKINES

9.5.2.4.2 INTERFERONS (INFS)

9.5.2.4.3 INTERLEUKINS (ILS)

9.5.2.4.4 HEMATOPOIETIC GROWTH FACTORS

9.5.2.4.5 BCG

9.5.2.4.6 IMMUNOMODULATORY DRUGS/BIOLOGICAL RESPONSE MODIFIERS

9.5.2.4.7 THALIDOMIDE (THALOMID)

9.5.2.4.8 LENALIDOMIDE (REVLIMID)

9.5.2.4.9 POMALIDOMIDE (POMALYST)

9.5.2.4.10 IMIQUIMOD (ALDARA, ZYCLARA)

9.5.2.4.11 OTHERS

9.5.2.5 TREATMENT VACCINES

9.5.2.6 OTHERS

9.5.3 HORMONAL THERAPY

9.5.3.1 SIGNAL TRANSDUCTION INHIBITORS

9.5.3.2 GENE EXPRESSION MODULATORS

9.5.3.3 APOPTOSIS INDUCERS

9.5.3.4 ANGIOGENESIS INHIBITORS

9.5.3.5 GENE THERAPY

9.5.3.6 OTHERS

9.6 OTHERS

10 GLOBAL, EUROPE, AUSTRALIA & U.S. CANCER TREATMENT MARKET, BY ROUTE OF ADMINISTRATION

10.1 OVERVIEW

10.2 INJECTABLE

10.3 ORAL

10.4 OTHERS

11 GLOBAL, EUROPE, AUSTRALIA & U.S. CANCER TREATMENT MARKET, BY END USER

11.1 OVERVIEW

11.2 HOSPITALS

11.3 SPECIALTY CLINICS

12 GLOBAL, EUROPE, AUSTRALIA & U.S. CANCER TREATMENT MARKET, BY REGION

12.1 OVERVIEW

12.2 EUROPE

12.2.1 GERMANY

12.2.2 FRANCE

12.2.3 U.K.

12.2.4 ITALY

12.2.5 SPAIN

12.2.6 NETHERLANDS

12.2.7 DENMARK

12.2.8 SWITZERLAND

12.2.9 SWEDEN

12.2.10 AUSTRIA

12.2.11 NORWAY

12.2.12 HUNGARY

12.2.13 GREECE

12.2.14 IRELAND

12.2.15 POLAND

12.2.16 REST OF EUROPE

12.3 AUSTRALIA

12.4 U.S.

12.5 CANADA

13 GLOBAL, EUROPE, AUSTRALIA & U.S. CANCER TREATMENT MARKET: COMPANY LANDSCAPE

13.1 COMPANY SHARE ANALYSIS: GLOBAL

13.2 COMPANY SHARE ANALYSIS: EUROPE

14 QUESTIONNAIRE

15 RELATED REPORTS

Список таблиц

TABLE 1 DIFFERENCES IN APPROVAL TIMES BETWEEN EMEA AND FDA FOR SELECTED TARGETED THERAPIES SINCE 2001

TABLE 2 NEW CANCER CASES, AGES 85+ IN THE U.S.

TABLE 3 DEATH CAUSES DUE TO CANCER, AGES 85+ IN THE U.S.

TABLE 4 HERE ARE SOME STATISTICS RELATED TO THE TREATMENT COST:

TABLE 5 GLOBAL, EUROPE, AUSTRALIA & U.S. CANCER TREATMENT MARKET, BY CANCER TYPE, 2020-2029 (USD MILLION)

TABLE 6 GLOBAL BREAST CANCER IN CANCER TREATMENT MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 7 GLOBAL COLORECTAL CANCER WITH LIVER METASTASES IN CANCER TREATMENT MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 8 GLOBAL LUNG CARCINOMA IN CANCER TREATMENT MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 9 GLOBAL PROSTATE CANCER IN CANCER TREATMENT MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 10 GLOBAL OVARIAN CANCER IN CANCER TREATMENT MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 11 GLOBAL HEAD-AND-NECK CANCER IN CANCER TREATMENT MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 12 GLOBAL PANCREATIC CANCER IN CANCER TREATMENT MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 13 GLOBAL GLIOBLASTOMA IN CANCER TREATMENT MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 14 GLOBAL RENAL CELL CARCINOMA IN CANCER TREATMENT MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 15 GLOBAL ANAPLASTIC THYROID CARCINOMA IN CANCER TREATMENT MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 16 GLOBAL SARCOMA IN CANCER TREATMENT MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 17 GLOBAL, EUROPE, AUSTRALIA & U.S. CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 18 GLOBAL MEDICATION IN CANCER TREATMENT MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 19 GLOBAL MEDICATION IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 20 GLOBAL BY DRUG TYPE IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 21 GLOBAL LUNG CARCINOMA IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 22 GLOBAL LUNG CARCINOMA IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 23 GLOBAL OVARIAN CANCER IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 24 GLOBAL HEAD-AND-NECK CANCER IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 25 GLOBAL RENAL CELL CARCINOMA IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 26 GLOBAL ANAPLASTIC THYROID CARCINOMA IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 27 GLOBAL BREAST CANCER IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 28 GLOBAL PROSTATE CANCER IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 29 GLOBAL PANCREATIC CANCER IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 30 GLOBAL GLIOBLASTOMA IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 31 GLOBAL SARCOMA IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 32 GLOBAL BY VACCINES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 33 GLOBAL RADIOTHERAPY IN CANCER TREATMENT MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 34 GLOBAL RADIOTHERAPY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 35 GLOBAL EXTERNAL BEAM RADIATION THERAPY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 36 GLOBAL INTERNAL RADIATION THERAPY (BRACHYTHERAPY) IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 37 GLOBAL SYSTEMIC RADIATION THERAPY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 38 GLOBAL SURGERY IN CANCER TREATMENT MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 39 GLOBAL SURGERY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 40 GLOBAL TARGETED THERAPIES IN CANCER TREATMENT MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 41 GLOBAL TARGETED THERAPIES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 42 GLOBAL SMALL MOLECULES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 43 GLOBAL TYROSINE & SERINE/THREONINE KINASES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 44 GLOBAL PROTEOSOMES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 45 GLOBAL MMPS AND HSPS IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 46 GLOBAL APOPTOSIS IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 47 GLOBAL IMMUNOTHERAPY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 48 GLOBAL T-CELL TRANSFER THERAPY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 49 GLOBAL BY PRODUCT IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 50 GLOBAL BY TECHNOLOGY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 51 GLOBAL MONOCLONAL ANTIBODIES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 52 GLOBAL IMMUNE SYSTEM MODULATORS IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 53 GLOBAL HORMONAL THERAPY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 54 GLOBAL OTHERS IN CANCER TREATMENT MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 55 GLOBAL, EUROPE, AUSTRALIA & U.S. CANCER TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 56 GLOBAL INJECTABLE IN CANCER TREATMENT MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 57 GLOBAL ORAL IN CANCER TREATMENT MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 58 GLOBAL OTHERS IN CANCER TREATMENT MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 59 GLOBAL, EUROPE, AUSTRALIA & U.S. CANCER TREATMENT MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 60 GLOBAL HOSPITALS IN CANCER TREATMENT MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 61 GLOBAL SPECIALTY CLINICS IN CANCER TREATMENT MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 62 GLOBAL, EUROPE, AUSTRALIA & U.S. CANCER TREATMENT MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 63 EUROPE CANCER TREATMENT MARKET, BY COUNTRY, 2020-2029 (USD MILLION)

TABLE 64 EUROPE CANCER TREATMENT MARKET, BY CANCER TYPE, 2020-2029 (USD MILLION)

TABLE 65 EUROPE CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 66 EUROPE MEDICATION IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 67 EUROPE BY DRUG TYPE IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 68 EUROPE LUNG CARCINOMA IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 69 EUROPE COLORECTAL CANCER WITH LIVER METASTASES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 70 EUROPE OVARIAN CANCER IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 71 EUROPE HEAD-AND-NECK CANCER IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 72 EUROPE RENAL CELL CARCINOMA IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 73 EUROPE ANAPLASTIC THYROID CARCINOMA IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 74 EUROPE BREAST CANCER IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 75 EUROPE PROSTATE CANCER IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 76 EUROPE PANCREATIC CANCER IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 77 EUROPE GLIOBLASTOMA IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 78 EUROPE SARCOMA IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 79 EUROPE BY VACCINES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 80 EUROPE RADIOTHERAPY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 81 EUROPE EXTERNAL BEAM RADIATION THERAPY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 82 EUROPE INTERNAL RADIATION THERAPY (BRACHYTHERAPY) IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 83 EUROPE SYSTEMIC RADIATION THERAPY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 84 EUROPE SURGERY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 85 EUROPE TARGETED THERAPIES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 86 EUROPE SMALL MOLECULES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 87 EUROPE TYROSINE & SERINE/THREONINE KINASES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 88 EUROPE PROTEOSOMES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 89 EUROPE MMPS AND HSPS IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 90 EUROPE APOPTOSIS IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 91 EUROPE IMMUNOTHERAPY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 92 EUROPE T-CELL TRANSFER THERAPY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 93 EUROPE BY PRODUCT IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 94 EUROPE BY TECHNOLOGY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 95 EUROPE MONOCLONAL ANTIBODIES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 96 EUROPE IMMUNE SYSTEM MODULATORS IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 97 EUROPE HORMONAL THERAPY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 98 EUROPE CANCER TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 99 EUROPE CANCER TREATMENT MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 100 GERMANY CANCER TREATMENT MARKET, BY CANCER TYPE, 2020-2029 (USD MILLION)

TABLE 101 GERMANY CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 102 GERMANY MEDICATION IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 103 GERMANY BY DRUG TYPE IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 104 GERMANY LUNG CARCINOMA IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 105 GERMANY COLORECTAL CANCER WITH LIVER METASTASES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 106 GERMANY OVARIAN CANCER IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 107 GERMANY HEAD-AND-NECK CANCER IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 108 GERMANY RENAL CELL CARCINOMA IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 109 GERMANY ANAPLASTIC THYROID CARCINOMA IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 110 GERMANY BREAST CANCER IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 111 GERMANY PROSTATE CANCER IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 112 GERMANY PANCREATIC CANCER IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 113 GERMANY GLIOBLASTOMA IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 114 GERMANY SARCOMA IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 115 GERMANY BY VACCINES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 116 GERMANY RADIOTHERAPY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 117 GERMANY EXTERNAL BEAM RADIATION THERAPY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 118 GERMANY INTERNAL RADIATION THERAPY (BRACHYTHERAPY) IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 119 GERMANY SYSTEMIC RADIATION THERAPY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 120 GERMANY SURGERY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 121 GERMANY TARGETED THERAPIES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 122 GERMANY SMALL MOLECULES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 123 GERMANY TYROSINE & SERINE/THREONINE KINASES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 124 GERMANY PROTEOSOMES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 125 GERMANY MMPS AND HSPS IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 126 GERMANY APOPTOSIS IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 127 GERMANY IMMUNOTHERAPY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 128 GERMANY T-CELL TRANSFER THERAPY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 129 GERMANY BY PRODUCT IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 130 GERMANY BY TECHNOLOGY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 131 GERMANY MONOCLONAL ANTIBODIES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 132 GERMANY IMMUNE SYSTEM MODULATORS IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 133 GERMANY HORMONAL THERAPY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 134 GERMANY CANCER TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 135 GERMANY CANCER TREATMENT MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 136 FRANCE CANCER TREATMENT MARKET, BY CANCER TYPE, 2020-2029 (USD MILLION)

TABLE 137 FRANCE CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 138 FRANCE MEDICATION IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 139 FRANCE BY DRUG TYPE IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 140 FRANCE LUNG CARCINOMA IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 141 FRANCE COLORECTAL CANCER WITH LIVER METASTASES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 142 FRANCE OVARIAN CANCER IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 143 FRANCE HEAD-AND-NECK CANCER IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 144 FRANCE RENAL CELL CARCINOMA IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 145 FRANCE ANAPLASTIC THYROID CARCINOMA IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 146 FRANCE BREAST CANCER IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 147 FRANCE PROSTATE CANCER IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 148 FRANCE PANCREATIC CANCER IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 149 FRANCE GLIOBLASTOMA IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 150 FRANCE SARCOMA IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 151 FRANCE BY VACCINES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 152 FRANCE RADIOTHERAPY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 153 FRANCE EXTERNAL BEAM RADIATION THERAPY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 154 FRANCE INTERNAL RADIATION THERAPY (BRACHYTHERAPY) IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 155 FRANCE SYSTEMIC RADIATION THERAPY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 156 FRANCE SURGERY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 157 FRANCE TARGETED THERAPIES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 158 FRANCE SMALL MOLECULES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 159 FRANCE TYROSINE & SERINE/THREONINE KINASES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 160 FRANCE PROTEOSOMES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 161 FRANCE MMPS AND HSPS IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 162 FRANCE APOPTOSIS IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 163 FRANCE IMMUNOTHERAPY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 164 FRANCE T-CELL TRANSFER THERAPY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 165 FRANCE BY PRODUCT IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 166 FRANCE BY TECHNOLOGY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 167 FRANCE MONOCLONAL ANTIBODIES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 168 FRANCE IMMUNE SYSTEM MODULATORS IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 169 FRANCE HORMONAL THERAPY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 170 FRANCE CANCER TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 171 FRANCE CANCER TREATMENT MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 172 U.K. CANCER TREATMENT MARKET, BY CANCER TYPE, 2020-2029 (USD MILLION)

TABLE 173 U.K. CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 174 U.K. MEDICATION IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 175 U.K. BY DRUG TYPE IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 176 U.K. LUNG CARCINOMA IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 177 U.K. COLORECTAL CANCER WITH LIVER METASTASES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 178 U.K. OVARIAN CANCER IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 179 U.K. HEAD-AND-NECK CANCER IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 180 U.K. RENAL CELL CARCINOMA IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 181 U.K. ANAPLASTIC THYROID CARCINOMA IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 182 U.K. BREAST CANCER IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 183 U.K. PROSTATE CANCER IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 184 U.K. PANCREATIC CANCER IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 185 U.K. GLIOBLASTOMA IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 186 U.K. SARCOMA IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 187 U.K. BY VACCINES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 188 U.K. RADIOTHERAPY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 189 U.K. EXTERNAL BEAM RADIATION THERAPY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 190 U.K. INTERNAL RADIATION THERAPY (BRACHYTHERAPY) IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 191 U.K. SYSTEMIC RADIATION THERAPY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 192 U.K. SURGERY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 193 U.K. TARGETED THERAPIES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 194 U.K. SMALL MOLECULES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 195 U.K. TYROSINE & SERINE/THREONINE KINASES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 196 U.K. PROTEOSOMES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 197 U.K. MMPS AND HSPS IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 198 U.K. APOPTOSIS IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 199 U.K. IMMUNOTHERAPY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 200 U.K. T-CELL TRANSFER THERAPY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 201 U.K. BY PRODUCT IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 202 U.K. BY TECHNOLOGY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 203 U.K. MONOCLONAL ANTIBODIES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 204 U.K. IMMUNE SYSTEM MODULATORS IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 205 U.K. HORMONAL THERAPY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 206 U.K. CANCER TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 207 U.K. CANCER TREATMENT MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 208 ITALY CANCER TREATMENT MARKET, BY CANCER TYPE, 2020-2029 (USD MILLION)

TABLE 209 ITALY CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 210 ITALY MEDICATION IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 211 ITALY BY DRUG TYPE IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 212 ITALY LUNG CARCINOMA IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 213 ITALY COLORECTAL CANCER WITH LIVER METASTASES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 214 ITALY OVARIAN CANCER IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 215 ITALY HEAD-AND-NECK CANCER IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 216 ITALY RENAL CELL CARCINOMA IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 217 ITALY ANAPLASTIC THYROID CARCINOMA IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 218 ITALY BREAST CANCER IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 219 ITALY PROSTATE CANCER IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 220 ITALY PANCREATIC CANCER IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 221 ITALY GLIOBLASTOMA IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 222 ITALY SARCOMA IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 223 ITALY BY VACCINES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 224 ITALY RADIOTHERAPY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 225 ITALY EXTERNAL BEAM RADIATION THERAPY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 226 ITALY INTERNAL RADIATION THERAPY (BRACHYTHERAPY) IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 227 ITALY SYSTEMIC RADIATION THERAPY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 228 ITALY SURGERY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 229 ITALY TARGETED THERAPIES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 230 ITALY SMALL MOLECULES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 231 ITALY TYROSINE & SERINE/THREONINE KINASES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 232 ITALY PROTEOSOMES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 233 ITALY MMPS AND HSPS IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 234 ITALY APOPTOSIS IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 235 ITALY IMMUNOTHERAPY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 236 ITALY T-CELL TRANSFER THERAPY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 237 ITALY BY PRODUCT IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 238 ITALY BY TECHNOLOGY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 239 ITALY MONOCLONAL ANTIBODIES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 240 ITALY IMMUNE SYSTEM MODULATORS IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 241 ITALY HORMONAL THERAPY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 242 ITALY CANCER TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 243 ITALY CANCER TREATMENT MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 244 SPAIN CANCER TREATMENT MARKET, BY CANCER TYPE, 2020-2029 (USD MILLION)

TABLE 245 SPAIN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 246 SPAIN MEDICATION IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 247 SPAIN BY DRUG TYPE IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 248 SPAIN LUNG CARCINOMA IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 249 SPAIN COLORECTAL CANCER WITH LIVER METASTASES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 250 SPAIN OVARIAN CANCER IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 251 SPAIN HEAD-AND-NECK CANCER IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 252 SPAIN RENAL CELL CARCINOMA IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 253 SPAIN ANAPLASTIC THYROID CARCINOMA IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 254 SPAIN BREAST CANCER IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 255 SPAIN PROSTATE CANCER IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 256 SPAIN PANCREATIC CANCER IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 257 SPAIN GLIOBLASTOMA IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 258 SPAIN SARCOMA IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 259 SPAIN BY VACCINES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 260 SPAIN RADIOTHERAPY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 261 SPAIN EXTERNAL BEAM RADIATION THERAPY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 262 SPAIN INTERNAL RADIATION THERAPY (BRACHYTHERAPY) IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 263 SPAIN SYSTEMIC RADIATION THERAPY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 264 SPAIN SURGERY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 265 SPAIN TARGETED THERAPIES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 266 SPAIN SMALL MOLECULES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 267 SPAIN TYROSINE & SERINE/THREONINE KINASES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 268 SPAIN PROTEOSOMES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 269 SPAIN MMPS AND HSPS IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 270 SPAIN APOPTOSIS IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 271 SPAIN IMMUNOTHERAPY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 272 SPAIN T-CELL TRANSFER THERAPY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 273 SPAIN BY PRODUCT IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 274 SPAIN BY TECHNOLOGY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 275 SPAIN MONOCLONAL ANTIBODIES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 276 SPAIN IMMUNE SYSTEM MODULATORS IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 277 SPAIN HORMONAL THERAPY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 278 SPAIN CANCER TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 279 SPAIN CANCER TREATMENT MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 280 NETHERLANDS CANCER TREATMENT MARKET, BY CANCER TYPE, 2020-2029 (USD MILLION)

TABLE 281 NETHERLANDS CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 282 NETHERLANDS MEDICATION IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 283 NETHERLANDS BY DRUG TYPE IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 284 NETHERLANDS LUNG CARCINOMA IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 285 NETHERLANDS COLORECTAL CANCER WITH LIVER METASTASES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 286 NETHERLANDS OVARIAN CANCER IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 287 NETHERLANDS HEAD-AND-NECK CANCER IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 288 NETHERLANDS RENAL CELL CARCINOMA IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 289 NETHERLANDS ANAPLASTIC THYROID CARCINOMA IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 290 NETHERLANDS BREAST CANCER IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 291 NETHERLANDS PROSTATE CANCER IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 292 NETHERLANDS PANCREATIC CANCER IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 293 NETHERLANDS GLIOBLASTOMA IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 294 NETHERLANDS SARCOMA IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 295 NETHERLANDS BY VACCINES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 296 NETHERLANDS RADIOTHERAPY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 297 NETHERLANDS EXTERNAL BEAM RADIATION THERAPY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 298 NETHERLANDS INTERNAL RADIATION THERAPY (BRACHYTHERAPY) IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 299 NETHERLANDS SYSTEMIC RADIATION THERAPY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 300 NETHERLANDS SURGERY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 301 NETHERLANDS TARGETED THERAPIES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 302 NETHERLANDS SMALL MOLECULES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 303 NETHERLANDS TYROSINE & SERINE/THREONINE KINASES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 304 NETHERLANDS PROTEOSOMES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 305 NETHERLANDS MMPS AND HSPS IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 306 NETHERLANDS APOPTOSIS IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 307 NETHERLANDS IMMUNOTHERAPY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 308 NETHERLANDS T-CELL TRANSFER THERAPY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 309 NETHERLANDS BY PRODUCT IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 310 NETHERLANDS BY TECHNOLOGY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 311 NETHERLANDS MONOCLONAL ANTIBODIES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 312 NETHERLANDS IMMUNE SYSTEM MODULATORS IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 313 NETHERLANDS HORMONAL THERAPY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 314 NETHERLANDS CANCER TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 315 NETHERLANDS CANCER TREATMENT MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 316 DENMARK CANCER TREATMENT MARKET, BY CANCER TYPE, 2020-2029 (USD MILLION)

TABLE 317 DENMARK CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 318 DENMARK MEDICATION IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 319 DENMARK BY DRUG TYPE IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 320 DENMARK LUNG CARCINOMA IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 321 DENMARK COLORECTAL CANCER WITH LIVER METASTASES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 322 DENMARK OVARIAN CANCER IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 323 DENMARK HEAD-AND-NECK CANCER IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 324 DENMARK RENAL CELL CARCINOMA IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 325 DENMARK ANAPLASTIC THYROID CARCINOMA IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 326 DENMARK BREAST CANCER IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 327 DENMARK PROSTATE CANCER IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 328 DENMARK PANCREATIC CANCER IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 329 DENMARK GLIOBLASTOMA IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 330 DENMARK SARCOMA IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 331 DENMARK BY VACCINES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 332 DENMARK RADIOTHERAPY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 333 DENMARK EXTERNAL BEAM RADIATION THERAPY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 334 DENMARK INTERNAL RADIATION THERAPY (BRACHYTHERAPY) IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 335 DENMARK SYSTEMIC RADIATION THERAPY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 336 DENMARK SURGERY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 337 DENMARK TARGETED THERAPIES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 338 DENMARK SMALL MOLECULES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 339 DENMARK TYROSINE & SERINE/THREONINE KINASES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 340 DENMARK PROTEOSOMES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 341 DENMARK MMPS AND HSPS IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 342 DENMARK APOPTOSIS IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 343 DENMARK IMMUNOTHERAPY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 344 DENMARK T-CELL TRANSFER THERAPY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 345 DENMARK BY PRODUCT IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 346 DENMARK BY TECHNOLOGY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 347 DENMARK MONOCLONAL ANTIBODIES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 348 DENMARK IMMUNE SYSTEM MODULATORS IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 349 DENMARK HORMONAL THERAPY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 350 DENMARK CANCER TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 351 DENMARK CANCER TREATMENT MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 352 SWITZERLAND CANCER TREATMENT MARKET, BY CANCER TYPE, 2020-2029 (USD MILLION)

TABLE 353 SWITZERLAND CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 354 SWITZERLAND MEDICATION IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 355 SWITZERLAND BY DRUG TYPE IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 356 SWITZERLAND LUNG CARCINOMA IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 357 SWITZERLAND COLORECTAL CANCER WITH LIVER METASTASES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 358 SWITZERLAND OVARIAN CANCER IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 359 SWITZERLAND HEAD-AND-NECK CANCER IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 360 SWITZERLAND RENAL CELL CARCINOMA IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 361 SWITZERLAND ANAPLASTIC THYROID CARCINOMA IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 362 SWITZERLAND BREAST CANCER IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 363 SWITZERLAND PROSTATE CANCER IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 364 SWITZERLAND PANCREATIC CANCER IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 365 SWITZERLAND GLIOBLASTOMA IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 366 SWITZERLAND SARCOMA IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 367 SWITZERLAND BY VACCINES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 368 SWITZERLAND RADIOTHERAPY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 369 SWITZERLAND EXTERNAL BEAM RADIATION THERAPY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 370 SWITZERLAND INTERNAL RADIATION THERAPY (BRACHYTHERAPY) IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 371 SWITZERLAND SYSTEMIC RADIATION THERAPY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 372 SWITZERLAND SURGERY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 373 SWITZERLAND TARGETED THERAPIES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 374 SWITZERLAND SMALL MOLECULES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 375 SWITZERLAND TYROSINE & SERINE/THREONINE KINASES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 376 SWITZERLAND PROTEOSOMES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 377 SWITZERLAND MMPS AND HSPS IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 378 SWITZERLAND APOPTOSIS IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 379 SWITZERLAND IMMUNOTHERAPY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 380 SWITZERLAND T-CELL TRANSFER THERAPY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 381 SWITZERLAND BY PRODUCT IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 382 SWITZERLAND BY TECHNOLOGY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 383 SWITZERLAND MONOCLONAL ANTIBODIES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 384 SWITZERLAND IMMUNE SYSTEM MODULATORS IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 385 SWITZERLAND HORMONAL THERAPY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 386 SWITZERLAND CANCER TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 387 SWITZERLAND CANCER TREATMENT MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 388 SWEDEN CANCER TREATMENT MARKET, BY CANCER TYPE, 2020-2029 (USD MILLION)

TABLE 389 SWEDEN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 390 SWEDEN MEDICATION IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 391 SWEDEN BY DRUG TYPE IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 392 SWEDEN LUNG CARCINOMA IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 393 SWEDEN COLORECTAL CANCER WITH LIVER METASTASES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 394 SWEDEN OVARIAN CANCER IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 395 SWEDEN HEAD-AND-NECK CANCER IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 396 SWEDEN RENAL CELL CARCINOMA IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 397 SWEDEN ANAPLASTIC THYROID CARCINOMA IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 398 SWEDEN BREAST CANCER IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 399 SWEDEN PROSTATE CANCER IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 400 SWEDEN PANCREATIC CANCER IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 401 SWEDEN GLIOBLASTOMA IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 402 SWEDEN SARCOMA IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 403 SWEDEN BY VACCINES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 404 SWEDEN RADIOTHERAPY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 405 SWEDEN EXTERNAL BEAM RADIATION THERAPY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 406 SWEDEN INTERNAL RADIATION THERAPY (BRACHYTHERAPY) IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 407 SWEDEN SYSTEMIC RADIATION THERAPY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 408 SWEDEN SURGERY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 409 SWEDEN TARGETED THERAPIES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 410 SWEDEN SMALL MOLECULES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 411 SWEDEN TYROSINE & SERINE/THREONINE KINASES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 412 SWEDEN PROTEOSOMES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 413 SWEDEN MMPS AND HSPS IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 414 SWEDEN APOPTOSIS IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 415 SWEDEN IMMUNOTHERAPY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 416 SWEDEN T-CELL TRANSFER THERAPY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 417 SWEDEN BY PRODUCT IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 418 SWEDEN BY TECHNOLOGY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 419 SWEDEN MONOCLONAL ANTIBODIES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 420 SWEDEN IMMUNE SYSTEM MODULATORS IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 421 SWEDEN HORMONAL THERAPY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 422 SWEDEN CANCER TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 423 SWEDEN CANCER TREATMENT MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 424 AUSTRIA CANCER TREATMENT MARKET, BY CANCER TYPE, 2020-2029 (USD MILLION)

TABLE 425 AUSTRIA CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 426 AUSTRIA MEDICATION IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 427 AUSTRIA BY DRUG TYPE IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 428 AUSTRIA LUNG CARCINOMA IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 429 AUSTRIA COLORECTAL CANCER WITH LIVER METASTASES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 430 AUSTRIA OVARIAN CANCER IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 431 AUSTRIA HEAD-AND-NECK CANCER IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 432 AUSTRIA RENAL CELL CARCINOMA IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 433 AUSTRIA ANAPLASTIC THYROID CARCINOMA IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 434 AUSTRIA BREAST CANCER IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 435 AUSTRIA PROSTATE CANCER IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 436 AUSTRIA PANCREATIC CANCER IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 437 AUSTRIA GLIOBLASTOMA IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 438 AUSTRIA SARCOMA IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 439 AUSTRIA BY VACCINES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 440 AUSTRIA RADIOTHERAPY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 441 AUSTRIA EXTERNAL BEAM RADIATION THERAPY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 442 AUSTRIA INTERNAL RADIATION THERAPY (BRACHYTHERAPY) IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 444 AUSTRIA SYSTEMIC RADIATION THERAPY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 445 AUSTRIA SURGERY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 446 AUSTRIA TARGETED THERAPIES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 447 AUSTRIA SMALL MOLECULES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 448 AUSTRIA TYROSINE & SERINE/THREONINE KINASES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 449 AUSTRIA PROTEOSOMES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 450 AUSTRIA MMPS AND HSPS IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 451 AUSTRIA APOPTOSIS IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 452 AUSTRIA IMMUNOTHERAPY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 453 AUSTRIA T-CELL TRANSFER THERAPY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 454 AUSTRIA BY PRODUCT IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 455 AUSTRIA BY TECHNOLOGY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 456 AUSTRIA MONOCLONAL ANTIBODIES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 457 AUSTRIA IMMUNE SYSTEM MODULATORS IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 458 AUSTRIA HORMONAL THERAPY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 459 AUSTRIA CANCER TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 460 AUSTRIA CANCER TREATMENT MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 461 NORWAY CANCER TREATMENT MARKET, BY CANCER TYPE, 2020-2029 (USD MILLION)

TABLE 462 NORWAY CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 463 NORWAY MEDICATION IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 464 NORWAY BY DRUG TYPE IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 465 NORWAY LUNG CARCINOMA IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 466 NORWAY COLORECTAL CANCER WITH LIVER METASTASES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 467 NORWAY OVARIAN CANCER IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 468 NORWAY HEAD-AND-NECK CANCER IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 469 NORWAY RENAL CELL CARCINOMA IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 470 NORWAY ANAPLASTIC THYROID CARCINOMA IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 471 NORWAY BREAST CANCER IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 472 NORWAY PROSTATE CANCER IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 473 NORWAY PANCREATIC CANCER IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 474 NORWAY GLIOBLASTOMA IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 475 NORWAY SARCOMA IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 476 NORWAY BY VACCINES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 477 NORWAY RADIOTHERAPY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 478 NORWAY EXTERNAL BEAM RADIATION THERAPY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 479 NORWAY INTERNAL RADIATION THERAPY (BRACHYTHERAPY) IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 480 NORWAY SYSTEMIC RADIATION THERAPY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 481 NORWAY SURGERY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 482 NORWAY TARGETED THERAPIES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 483 NORWAY SMALL MOLECULES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 484 NORWAY TYROSINE & SERINE/THREONINE KINASES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 485 NORWAY PROTEOSOMES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 486 NORWAY MMPS AND HSPS IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 487 NORWAY APOPTOSIS IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 488 NORWAY IMMUNOTHERAPY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 489 NORWAY T-CELL TRANSFER THERAPY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 490 NORWAY BY PRODUCT IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 491 NORWAY BY TECHNOLOGY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 492 NORWAY MONOCLONAL ANTIBODIES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 493 NORWAY IMMUNE SYSTEM MODULATORS IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 494 NORWAY HORMONAL THERAPY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 495 NORWAY CANCER TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 496 NORWAY CANCER TREATMENT MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 497 HUNGARY CANCER TREATMENT MARKET, BY CANCER TYPE, 2020-2029 (USD MILLION)

TABLE 498 HUNGARY CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 499 HUNGARY MEDICATION IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 500 HUNGARY BY DRUG TYPE IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 501 HUNGARY LUNG CARCINOMA IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 502 HUNGARY COLORECTAL CANCER WITH LIVER METASTASES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 503 HUNGARY OVARIAN CANCER IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 504 HUNGARY HEAD-AND-NECK CANCER IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 505 HUNGARY RENAL CELL CARCINOMA IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 506 HUNGARY ANAPLASTIC THYROID CARCINOMA IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 507 HUNGARY BREAST CANCER IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 508 HUNGARY PROSTATE CANCER IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 509 HUNGARY PANCREATIC CANCER IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 510 HUNGARY GLIOBLASTOMA IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 511 HUNGARY SARCOMA IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 512 HUNGARY BY VACCINES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 513 HUNGARY RADIOTHERAPY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 514 HUNGARY EXTERNAL BEAM RADIATION THERAPY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 515 HUNGARY INTERNAL RADIATION THERAPY (BRACHYTHERAPY) IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 516 HUNGARY SYSTEMIC RADIATION THERAPY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 517 HUNGARY SURGERY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 518 HUNGARY TARGETED THERAPIES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 519 HUNGARY SMALL MOLECULES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 520 HUNGARY TYROSINE & SERINE/THREONINE KINASES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 521 HUNGARY PROTEOSOMES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 522 HUNGARY MMPS AND HSPS IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 523 HUNGARY APOPTOSIS IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 524 HUNGARY IMMUNOTHERAPY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 525 HUNGARY T-CELL TRANSFER THERAPY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 526 HUNGARY BY PRODUCT IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 527 HUNGARY BY TECHNOLOGY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 528 HUNGARY MONOCLONAL ANTIBODIES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 529 HUNGARY IMMUNE SYSTEM MODULATORS IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 530 HUNGARY HORMONAL THERAPY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 531 HUNGARY CANCER TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 532 HUNGARY CANCER TREATMENT MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 533 GREECE CANCER TREATMENT MARKET, BY CANCER TYPE, 2020-2029 (USD MILLION)

TABLE 534 GREECE CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 535 GREECE MEDICATION IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 536 GREECE BY DRUG TYPE IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 537 GREECE LUNG CARCINOMA IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 538 GREECE COLORECTAL CANCER WITH LIVER METASTASES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 539 GREECE OVARIAN CANCER IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 540 GREECE HEAD-AND-NECK CANCER IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 541 GREECE RENAL CELL CARCINOMA IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 542 GREECE ANAPLASTIC THYROID CARCINOMA IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 543 GREECE BREAST CANCER IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 544 GREECE PROSTATE CANCER IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 545 GREECE PANCREATIC CANCER IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 546 GREECE GLIOBLASTOMA IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 547 GREECE SARCOMA IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 548 GREECE BY VACCINES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 549 GREECE RADIOTHERAPY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 550 GREECE EXTERNAL BEAM RADIATION THERAPY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 551 GREECE INTERNAL RADIATION THERAPY (BRACHYTHERAPY) IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 552 GREECE SYSTEMIC RADIATION THERAPY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 553 GREECE SURGERY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 554 GREECE TARGETED THERAPIES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 555 GREECE SMALL MOLECULES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 556 GREECE TYROSINE & SERINE/THREONINE KINASES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 557 GREECE PROTEOSOMES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 558 GREECE MMPS AND HSPS IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 559 GREECE APOPTOSIS IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 560 GREECE IMMUNOTHERAPY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 561 GREECE T-CELL TRANSFER THERAPY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 562 GREECE BY PRODUCT IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 563 GREECE BY TECHNOLOGY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 564 GREECE MONOCLONAL ANTIBODIES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 565 GREECE IMMUNE SYSTEM MODULATORS IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 566 GREECE HORMONAL THERAPY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 567 GREECE CANCER TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 568 GREECE CANCER TREATMENT MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 569 IRELAND CANCER TREATMENT MARKET, BY CANCER TYPE, 2020-2029 (USD MILLION)

TABLE 570 IRELAND CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 571 IRELAND MEDICATION IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 572 IRELAND BY DRUG TYPE IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 573 IRELAND LUNG CARCINOMA IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 574 IRELAND COLORECTAL CANCER WITH LIVER METASTASES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 575 IRELAND OVARIAN CANCER IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 576 IRELAND HEAD-AND-NECK CANCER IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 577 IRELAND RENAL CELL CARCINOMA IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 578 IRELAND ANAPLASTIC THYROID CARCINOMA IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 579 IRELAND BREAST CANCER IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 580 IRELAND PROSTATE CANCER IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 581 IRELAND PANCREATIC CANCER IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 582 IRELAND GLIOBLASTOMA IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 583 IRELAND SARCOMA IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 584 IRELAND BY VACCINES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 585 IRELAND RADIOTHERAPY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 586 IRELAND EXTERNAL BEAM RADIATION THERAPY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 587 IRELAND INTERNAL RADIATION THERAPY (BRACHYTHERAPY) IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 588 IRELAND SYSTEMIC RADIATION THERAPY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 589 IRELAND SURGERY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 590 IRELAND TARGETED THERAPIES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 591 IRELAND SMALL MOLECULES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 592 IRELAND TYROSINE & SERINE/THREONINE KINASES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 593 IRELAND PROTEOSOMES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 594 IRELAND MMPS AND HSPS IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 595 IRELAND APOPTOSIS IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 596 IRELAND IMMUNOTHERAPY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 597 IRELAND T-CELL TRANSFER THERAPY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 598 IRELAND BY PRODUCT IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 599 IRELAND BY TECHNOLOGY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 600 IRELAND MONOCLONAL ANTIBODIES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 601 IRELAND IMMUNE SYSTEM MODULATORS IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 602 IRELAND HORMONAL THERAPY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 603 IRELAND CANCER TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 604 IRELAND CANCER TREATMENT MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 605 POLAND CANCER TREATMENT MARKET, BY CANCER TYPE, 2020-2029 (USD MILLION)

TABLE 606 POLAND CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 607 POLAND MEDICATION IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 608 POLAND BY DRUG TYPE IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 609 POLAND LUNG CARCINOMA IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 610 POLAND COLORECTAL CANCER WITH LIVER METASTASES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 611 POLAND OVARIAN CANCER IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 612 POLAND HEAD-AND-NECK CANCER IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 613 POLAND RENAL CELL CARCINOMA IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 614 POLAND ANAPLASTIC THYROID CARCINOMA IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 615 POLAND BREAST CANCER IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 616 POLAND PROSTATE CANCER IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 617 POLAND PANCREATIC CANCER IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 618 POLAND GLIOBLASTOMA IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 619 POLAND SARCOMA IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 620 POLAND BY VACCINES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 621 POLAND RADIOTHERAPY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 622 POLAND EXTERNAL BEAM RADIATION THERAPY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 623 POLAND INTERNAL RADIATION THERAPY (BRACHYTHERAPY) IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 624 POLAND SYSTEMIC RADIATION THERAPY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 625 POLAND SURGERY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 626 POLAND TARGETED THERAPIES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 627 POLAND SMALL MOLECULES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 628 POLAND TYROSINE & SERINE/THREONINE KINASES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 629 POLAND PROTEOSOMES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 630 POLAND MMPS AND HSPS IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 631 POLAND APOPTOSIS IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 632 POLAND IMMUNOTHERAPY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 633 POLAND T-CELL TRANSFER THERAPY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 634 POLAND BY PRODUCT IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 635 POLAND BY TECHNOLOGY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 636 POLAND MONOCLONAL ANTIBODIES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 637 POLAND IMMUNE SYSTEM MODULATORS IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 638 POLAND HORMONAL THERAPY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 639 POLAND CANCER TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 640 POLAND CANCER TREATMENT MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 641 REST OF EUROPE CANCER TREATMENT MARKET, BY CANCER TYPE, 2020-2029 (USD MILLION)

TABLE 642 AUSTRALIA CANCER TREATMENT MARKET, BY CANCER TYPE, 2020-2029 (USD MILLION)

TABLE 643 AUSTRALIA CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 644 AUSTRALIA MEDICATION IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 645 AUSTRALIA BY DRUG TYPE IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 646 AUSTRALIA LUNG CARCINOMA IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 647 AUSTRALIA COLORECTAL CANCER WITH LIVER METASTASES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 648 AUSTRALIA OVARIAN CANCER IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 649 AUSTRALIA HEAD-AND-NECK CANCER IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 650 AUSTRALIA RENAL CELL CARCINOMA IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 651 AUSTRALIA ANAPLASTIC THYROID CARCINOMA IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 652 AUSTRALIA BREAST CANCER IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 653 AUSTRALIA PROSTATE CANCER IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 654 AUSTRALIA PANCREATIC CANCER IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 655 AUSTRALIA GLIOBLASTOMA IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 656 AUSTRALIA SARCOMA IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 657 AUSTRALIA BY VACCINES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 658 AUSTRALIA RADIOTHERAPY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 659 AUSTRALIA EXTERNAL BEAM RADIATION THERAPY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 660 AUSTRALIA INTERNAL RADIATION THERAPY (BRACHYTHERAPY) IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 661 AUSTRALIA SYSTEMIC RADIATION THERAPY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 662 AUSTRALIA SURGERY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 663 AUSTRALIA TARGETED THERAPIES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 664 AUSTRALIA SMALL MOLECULES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 665 AUSTRALIA TYROSINE & SERINE/THREONINE KINASES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 666 AUSTRALIA PROTEASOMES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 667 AUSTRALIA MMPS AND HSPS IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 668 AUSTRALIA APOPTOSIS IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 669 AUSTRALIA IMMUNOTHERAPY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 670 AUSTRALIA T-CELL TRANSFER THERAPY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 671 AUSTRALIA BY PRODUCT IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 672 AUSTRALIA BY TECHNOLOGY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 673 AUSTRALIA MONOCLONAL ANTIBODIES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 674 AUSTRALIA IMMUNE SYSTEM MODULATORS IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 675 AUSTRALIA HORMONAL THERAPY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 676 AUSTRALIA CANCER TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 677 AUSTRALIA CANCER TREATMENT MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 678 U.S. CANCER TREATMENT MARKET, BY CANCER TYPE, 2020-2029 (USD MILLION)

TABLE 679 U.S. CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 680 U.S. MEDICATION IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 681 U.S. BY DRUG TYPE IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 682 U.S. LUNG CARCINOMA IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 683 U.S. COLORECTAL CANCER WITH LIVER METASTASES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 684 U.S. OVARIAN CANCER IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 685 U.S. HEAD-AND-NECK CANCER IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 686 U.S. RENAL CELL CARCINOMA IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 687 U.S. ANAPLASTIC THYROID CARCINOMA IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 688 U.S. BREAST CANCER IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 689 U.S. PROSTATE CANCER IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 690 U.S. PANCREATIC CANCER IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 691 U.S. GLIOBLASTOMA IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 692 U.S. SARCOMA IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 693 U.S. BY VACCINES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 694 U.S. RADIOTHERAPY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 695 U.S. EXTERNAL BEAM RADIATION THERAPY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 696 U.S. INTERNAL RADIATION THERAPY (BRACHYTHERAPY) IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 697 U.S. SYSTEMIC RADIATION THERAPY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 698 U.S. SURGERY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 699 U.S. TARGETED THERAPIES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 700 U.S. SMALL MOLECULES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 701 U.S. TYROSINE & SERINE/THREONINE KINASES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 702 U.S. PROTEASOMES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 703 U.S. MMPS AND HSPS IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 704 U.S. APOPTOSIS IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 705 U.S. IMMUNOTHERAPY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 706 U.S. T-CELL TRANSFER THERAPY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 707 U.S. BY PRODUCT IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 708 U.S. BY TECHNOLOGY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 709 U.S. MONOCLONAL ANTIBODIES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 710 U.S. IMMUNE SYSTEM MODULATORS IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 711 U.S. HORMONAL THERAPY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 712 U.S. CANCER TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 713 U.S. CANCER TREATMENT MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 714 CANADA CANCER TREATMENT MARKET, BY CANCER TYPE, 2020-2029 (USD MILLION)

TABLE 715 CANADA CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 716 CANADA MEDICATION IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 717 CANADA BY DRUG TYPE IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 718 CANADA LUNG CARCINOMA IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 719 CANADA COLORECTAL CANCER WITH LIVER METASTASES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 720 CANADA OVARIAN CANCER IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 721 CANADA HEAD-AND-NECK CANCER IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 722 CANADA RENAL CELL CARCINOMA IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 723 CANADA ANAPLASTIC THYROID CARCINOMA IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 724 CANADA BREAST CANCER IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 725 CANADA PROSTATE CANCER IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 726 CANADA PANCREATIC CANCER IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 727 CANADA GLIOBLASTOMA IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 728 CANADA SARCOMA IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 729 CANADA BY VACCINES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 730 CANADA RADIOTHERAPY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 731 CANADA EXTERNAL BEAM RADIATION THERAPY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 732 CANADA INTERNAL RADIATION THERAPY (BRACHYTHERAPY) IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 733 CANADA SYSTEMIC RADIATION THERAPY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 734 CANADA SURGERY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 735 CANADA TARGETED THERAPIES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 736 CANADA SMALL MOLECULES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 737 CANADA TYROSINE & SERINE/THREONINE KINASES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 738 CANADA PROTEASOMES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 739 CANADA MMPS AND HSPS IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 740 CANADA APOPTOSIS IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 741 CANADA IMMUNOTHERAPY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 742 CANADA T-CELL TRANSFER THERAPY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 743 CANADA BY PRODUCT IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 744 CANADA BY TECHNOLOGY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 745 CANADA MONOCLONAL ANTIBODIES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 746 CANADA IMMUNE SYSTEM MODULATORS IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 747 CANADA HORMONAL THERAPY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 748 CANADA CANCER TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 749 CANADA CANCER TREATMENT MARKET, BY END USER, 2020-2029 (USD MILLION)

Список рисунков

FIGURE 1 GLOBAL, EUROPE, AUSTRALIA, U.S. CANCER TREATMENT MARKET: SEGMENTATION

FIGURE 2 GLOBAL, EUROPE, AUSTRALIA, U.S. CANCER TREATMENT MARKET: DATA TRIANGULATION

FIGURE 3 GLOBAL, EUROPE, AUSTRALIA, U.S. CANCER TREATMENT MARKET: DROC ANALYSIS

FIGURE 4 GLOBAL, EUROPE, AUSTRALIA, U.S. CANCER TREATMENT MARKET: GLOBAL VS REGIONAL MARKET ANALYSIS

FIGURE 5 GLOBAL, EUROPE, AUSTRALIA, U.S. CANCER TREATMENT MARKET: COMPANY RESEARCH ANALYSIS

FIGURE 6 GLOBAL, EUROPE, AUSTRALIA, U.S. CANCER TREATMENT MARKET: INTERVIEW DEMOGRAPHICS

FIGURE 7 GLOBAL, EUROPE, AUSTRALIA, U.S. CANCER TREATMENT MARKET: VENDOR SHARE ANALYSIS

FIGURE 8 GLOBAL, EUROPE, AUSTRALIA, U.S. CANCER TREATMENT MARKET: SEGMENTATION

FIGURE 9 HIGH PREVALENCE OF CANCER IS EXPECTED TO DRIVE THE GLOBAL, EUROPE, AUSTRALIA, U.S. CANCER TREATMENT MARKET IN THE FORECAST PERIOD OF 2022 TO 2029

FIGURE 10 BREAST CANCER SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE GLOBAL, EUROPE, AUSTRALIA, U.S. CANCER TREATMENT MARKET IN 2022 TO 2029

FIGURE 11 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF GLOBAL, EUROPE, AUSTRALIA, U.S. CANCER TREATMENT MARKET

FIGURE 12 ESTIMATED NUMBER OF NEW CASES AND DEATHS BY VARIOUS TYPES OF CANCER WORLDWIDE, 2020

FIGURE 13 ESTIMATED NUMBER OF NEW CASES IN 2018, WORLDWIDE, BOTH SEXES, ALL AGES

FIGURE 14 GLOBAL, EUROPE, AUSTRALIA & U.S. CANCER TREATMENT MARKET: BY CANCER TYPE, 2021

FIGURE 15 GLOBAL, EUROPE, AUSTRALIA & U.S. CANCER TREATMENT MARKET: BY CANCER TYPE, 2020-2029 (USD MILLION)

FIGURE 16 GLOBAL, EUROPE, AUSTRALIA & U.S. CANCER TREATMENT MARKET: BY CANCER TYPE, CAGR (2022-2029)

FIGURE 17 GLOBAL, EUROPE, AUSTRALIA & U.S. CANCER TREATMENT MARKET: BY CANCER TYPE, LIFELINE CURVE

FIGURE 18 GLOBAL, EUROPE, AUSTRALIA & U.S. CANCER TREATMENT MARKET: BY TREATMENT, 2021

FIGURE 19 GLOBAL, EUROPE, AUSTRALIA & U.S. CANCER TREATMENT MARKET: BY TREATMENT, 2020-2029 (USD MILLION)

FIGURE 20 GLOBAL, EUROPE, AUSTRALIA & U.S. CANCER TREATMENT MARKET: BY TREATMENT CAGR (2022-2029)

FIGURE 21 GLOBAL, EUROPE, AUSTRALIA & U.S. CANCER TREATMENT MARKET: BY TREATMENT LIFELINE CURVE

FIGURE 22 GLOBAL, EUROPE, AUSTRALIA & U.S. CANCER TREATMENT MARKET: BY ROUTE OF ADMINISTRATION, 2021

FIGURE 23 GLOBAL, EUROPE, AUSTRALIA & U.S. CANCER TREATMENT MARKET: BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

FIGURE 24 GLOBAL, EUROPE, AUSTRALIA & U.S. CANCER TREATMENT MARKET: BY ROUTE OF ADMINISTRATION, CAGR (2022-2029)

FIGURE 25 GLOBAL, EUROPE, AUSTRALIA & U.S. CANCER TREATMENT MARKET: BY ROUTE OF ADMINISTRATION LIFELINE CURVE

FIGURE 26 GLOBAL, EUROPE, AUSTRALIA & U.S. CANCER TREATMENT MARKET: BY END USER, 2021

FIGURE 27 GLOBAL, EUROPE, AUSTRALIA & U.S. CANCER TREATMENT MARKET: BY END USER, 2020-2029 (USD MILLION)

FIGURE 28 GLOBAL, EUROPE, AUSTRALIA & U.S. CANCER TREATMENT MARKET: BY END USER, CAGR (2022-2029)

FIGURE 29 GLOBAL, EUROPE, AUSTRALIA & U.S. CANCER TREATMENT MARKET: BY END USER LIFELINE CURVE

FIGURE 30 GLOBAL, EUROPE, AUSTRALIA & U.S. CANCER TREATMENT MARKET: SNAPSHOT (2021)

FIGURE 31 GLOBAL, EUROPE, AUSTRALIA & U.S. CANCER TREATMENT MARKET: BY REGION (2021)

FIGURE 32 GLOBAL, EUROPE, AUSTRALIA & U.S. CANCER TREATMENT MARKET: BY REGION (2022 & 2029)

FIGURE 33 GLOBAL, EUROPE, AUSTRALIA & U.S. CANCER TREATMENT MARKET: BY REGION (2021 & 2029)

FIGURE 34 GLOBAL, EUROPE, AUSTRALIA & U.S. CANCER TREATMENT MARKET: BY CANCER TYPE (2022-2029)

FIGURE 35 EUROPE CANCER TREATMENT MARKET: SNAPSHOT (2021)

FIGURE 36 EUROPE CANCER TREATMENT MARKET: BY COUNTRY (2021)

FIGURE 37 EUROPE CANCER TREATMENT MARKET: BY COUNTRY (2022 & 2029)

FIGURE 38 EUROPE CANCER TREATMENT MARKET: BY COUNTRY (2021 & 2029)

FIGURE 39 EUROPE CANCER TREATMENT MARKET: BY CANCER TYPE (2022-2029)

FIGURE 40 GLOBAL, EUROPE, AUSTRALIA & U.S. CANCER TREATMENT MARKET: COMPANY SHARE 2021 (%)

FIGURE 41 EUROPE CANCER TREATMENT MARKET: COMPANY SHARE 2021 (%)

View Detailed Information

Методология исследования

Сбор данных и анализ базового года выполняются с использованием модулей сбора данных с большими размерами выборки. Этап включает получение рыночной информации или связанных данных из различных источников и стратегий. Он включает изучение и планирование всех данных, полученных из прошлого заранее. Он также охватывает изучение несоответствий информации, наблюдаемых в различных источниках информации. Рыночные данные анализируются и оцениваются с использованием статистических и последовательных моделей рынка. Кроме того, анализ доли рынка и анализ ключевых тенденций являются основными факторами успеха в отчете о рынке. Чтобы узнать больше, пожалуйста, запросите звонок аналитика или оставьте свой запрос.

Ключевой методологией исследования, используемой исследовательской группой DBMR, является триангуляция данных, которая включает в себя интеллектуальный анализ данных, анализ влияния переменных данных на рынок и первичную (отраслевую экспертную) проверку. Модели данных включают сетку позиционирования поставщиков, анализ временной линии рынка, обзор рынка и руководство, сетку позиционирования компании, патентный анализ, анализ цен, анализ доли рынка компании, стандарты измерения, глобальный и региональный анализ и анализ доли поставщика. Чтобы узнать больше о методологии исследования, отправьте запрос, чтобы поговорить с нашими отраслевыми экспертами.

Доступна настройка

Data Bridge Market Research является лидером в области передовых формативных исследований. Мы гордимся тем, что предоставляем нашим существующим и новым клиентам данные и анализ, которые соответствуют и подходят их целям. Отчет можно настроить, включив в него анализ ценовых тенденций целевых брендов, понимание рынка для дополнительных стран (запросите список стран), данные о результатах клинических испытаний, обзор литературы, обновленный анализ рынка и продуктовой базы. Анализ рынка целевых конкурентов можно проанализировать от анализа на основе технологий до стратегий портфеля рынка. Мы можем добавить столько конкурентов, о которых вам нужны данные в нужном вам формате и стиле данных. Наша команда аналитиков также может предоставить вам данные в сырых файлах Excel, сводных таблицах (книга фактов) или помочь вам в создании презентаций из наборов данных, доступных в отчете.

Часто задаваемые вопросы

How big is the cancer treatment market?

The cancer treatment market size will be worth USD 524,921.84 million by 2029.

What is the growth rate of the cancer treatment market?

The growth rate of the cancer treatment market is 12.1%.

Which are the major companies in the cancer treatment market?

The major companies in the cancer treatment market are Bristol-Myers Squibb Company, F. Hoffman La-Roche Ltd, Clegen, AbbVie, Inc., Pfizer, Inc., and Novartis AG, among others.

What are the factors on which the cancer treatment market research is based on?

Cancer type, treatment, route of administration, and end user are the factors on which the cancer treatment market research is based.

What are the growth drivers of the cancer treatment market?

The high prevalence of cancer, growing geriatric cancer, and availability of advanced targeted therapies for cancer are the growth drivers of the cancer treatment market.

Глобальный рынок лечения рака – тенденции отрасли и прогноз до 2029 года

Глобальный рынок лечения рака – тенденции отрасли и прогноз до 2029 года

Global Cancer Treatment Market

CAGR : 12.10 %

Анализ рынка и аналитика : глобальный рынок лечения рака

Масштаб и размер мирового рынка лечения рака

Анализ мирового рынка лечения рака на уровне страны

Анализ конкурентной среды и доли мирового рынка лечения рака

Get online access to the report on the World's First Market Intelligence Cloud

Содержание

Список таблиц

Список рисунков

Методология исследования

Доступна настройка

Часто задаваемые вопросы

Отчеты

Обзор рынка

Поддерживать

Решения

Глобальный рынок лечения рака – тенденции отрасли и прогноз до 2029 года

Глобальный рынок лечения рака – тенденции отрасли и прогноз до 2029 года

Global Cancer Treatment Market

CAGR : 12.10 %

Анализ рынка и аналитика : глобальный рынок лечения рака

Масштаб и размер мирового рынка лечения рака

Анализ мирового рынка лечения рака на уровне страны

Анализ конкурентной среды и доли мирового рынка лечения рака

Get online access to the report on the World's First Market Intelligence Cloud

Содержание

Список таблиц

Список рисунков

Методология исследования

Доступна настройка

Часто задаваемые вопросы

Просмотр связанных страниц